Medexus Pharmaceuticals (MDP) Q1 2025 earnings summary

Executive summary

• Fiscal Q1 2025 delivered net income of $2 million, up $1.3 million year-over-year, and adjusted EBITDA of $6.1 million, down from $6.6 million last year, driven by cost reduction initiatives and improved operating costs.

• Revenue was $27.3 million, a decrease of 13.6% year-over-year, mainly due to lower Rasuvo and IXINITY sales, partially offset by Rupall growth.

• Management highlighted strong cash generation and record operating cash flow, supporting principal repayments on credit facilities.

• Cost reduction initiatives implemented in January 2024 led to lower operating expenses and improved cost structure.

Financial highlights

• Gross profit was $14.8 million, down from $17.2 million year-over-year.

• Gross margin held steady at 54.4% versus 54.6% last year, and improved sequentially from 51.2% in the previous quarter.

• Adjusted EBITDA margin was 22.4% for Q1 2025.

• Operating cash flow reached a record $8.2 million, with cash on hand rising to $8.5 million as of June 30, 2024.

• Selling and administrative expenses dropped to $10.3 million from $11.9 million year-over-year.

Outlook and guidance

• FDA review of treosulfan NDA expected to conclude by October 30, 2024, with commercial launch targeted for H1 2025 if approved.

• Treosulfan US revenue could exceed $100 million annually within five years post-launch, with significant impact expected from early fiscal 2026.

• Rupall faces generic competition in Canada after January 2025, likely resulting in price reductions and gradual revenue decline.

• IXINITY and Rasuvo expected to face continued revenue pressure from competition and statutory discounts.

• NYDA may benefit from upcoming Ontario legislation allowing pharmacists to prescribe, though impact is not yet quantifiable.